Gossamer Bio Balance Sheet Health
Financial Health criteria checks 4/6
Gossamer Bio has a total shareholder equity of $54.1M and total debt of $197.3M, which brings its debt-to-equity ratio to 364.4%. Its total assets and total liabilities are $350.9M and $296.7M respectively.
Key information
364.4%
Debt to equity ratio
US$197.29m
Debt
| Interest coverage ratio | n/a |
| Cash | US$327.03m |
| Equity | US$54.14m |
| Total liabilities | US$296.74m |
| Total assets | US$350.88m |
Recent financial health updates
Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?
Jun 25
Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?
Jan 19Recent updates
Gossamer Bio Has One More Shot On Goal And Is Not Likely To Miss
Sep 10Brokers Are Upgrading Their Views On Gossamer Bio, Inc. (NASDAQ:GOSS) With These New Forecasts
Aug 14Peaking Back In On Gossamer Bio
Sep 27Gossamer Bio to raise $120M in a private equity placement
Jul 13Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?
Jun 25Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?
Jan 19Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?
Sep 22Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares
Jan 28Gossamer Bio (GOSS) Investor Presentation - Slideshow
Nov 18Financial Position Analysis
Short Term Liabilities: GOSS's short term assets ($344.3M) exceed its short term liabilities ($51.1M).
Long Term Liabilities: GOSS's short term assets ($344.3M) exceed its long term liabilities ($245.7M).
Debt to Equity History and Analysis
Debt Level: GOSS has more cash than its total debt.
Reducing Debt: GOSS's debt to equity ratio has increased from 7.1% to 364.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GOSS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GOSS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 22:06 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Gossamer Bio, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Gould | Barclays |
| Zhilin Long | Berenberg |
| Patrick Trucchio | Berenberg |